Unicycive rises on narrower quarterly loss
UNCY•Shares rise after narrower quarterly loss and update on FDA filing
-
Shares of drug developer Unicycive Therapeutics UNCY.O rise 9.2% to $5.46
-
Co posted Q2 net loss of $1.7 million, compared to a net loss of $6.5 million a year ago
-
Co says the decreased net loss was attributed primarily to a decrease in the fair value of the co's warrant liability
-
UNCY plans to resubmit marketing application for oxylanthanum carbonate after FDA facility inspection
-
In June, U.S. FDA had declined to approve oxylanthanum carbonate to treat elevated phosphate levels in patients on dialysis due to chronic kidney diseases
-
Including session's move, stock down 5.9% YTD
